It was declared that the prevalence of MetS will increase to 31.0-55.0% in postmenopausal women, which is not only associated with aging, but also associated with the changes in sex hormones including estrogen, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) during the menopausal transition (3–5). This evidence concerns the gene PLOD1 and metabolic syndrome.